337 related articles for article (PubMed ID: 33379384)
1. Tissue-Resident Lymphocytes: Implications in Immunotherapy for Hepatocellular Carcinoma.
Han JW; Yoon SK
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379384
[TBL] [Abstract][Full Text] [Related]
2. Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade.
Bozward AG; Warricker F; Oo YH; Khakoo SI
Front Immunol; 2021; 12():643310. PubMed ID: 33995362
[TBL] [Abstract][Full Text] [Related]
3. Prospects and Challenges for T Cell-Based Therapies of HCC.
Woller N; Engelskircher SA; Wirth T; Wedemeyer H
Cells; 2021 Jun; 10(7):. PubMed ID: 34209393
[TBL] [Abstract][Full Text] [Related]
4. Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches.
Kalathil SG; Thanavala Y
Cells; 2021 May; 10(6):. PubMed ID: 34071188
[TBL] [Abstract][Full Text] [Related]
5. The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review.
Schoenberg MB; Li X; Li X; Han Y; Börner N; Koch D; Guba MO; Werner J; Bazhin AV
Int Immunopharmacol; 2021 Dec; 101(Pt A):108220. PubMed ID: 34673334
[TBL] [Abstract][Full Text] [Related]
6. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
Choi C; Yoo GS; Cho WK; Park HC
World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
[TBL] [Abstract][Full Text] [Related]
7. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
Oura K; Morishita A; Tani J; Masaki T
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy.
Patel K; Lamm R; Altshuler P; Dang H; Shah AP
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32942580
[TBL] [Abstract][Full Text] [Related]
9. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
10. Perspectives of immunotherapy in hepatocellular carcinoma (HCC).
Büttner N; Schmidt N; Thimme R
Z Gastroenterol; 2016 Dec; 54(12):1334-1342. PubMed ID: 27936483
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapeutic approaches for hepatocellular carcinoma.
Longo V; Gnoni A; Casadei Gardini A; Pisconti S; Licchetta A; Scartozzi M; Memeo R; Palmieri VO; Aprile G; Santini D; Nardulli P; Silvestris N; Brunetti O
Oncotarget; 2017 May; 8(20):33897-33910. PubMed ID: 28420805
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?
Repáraz D; Aparicio B; Llopiz D; Hervás-Stubbs S; Sarobe P
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216137
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
Liu Z; Liu X; Liang J; Liu Y; Hou X; Zhang M; Li Y; Jiang X
Front Immunol; 2021; 12():765101. PubMed ID: 34675942
[TBL] [Abstract][Full Text] [Related]
14. Immune responses in hepatocellular carcinoma.
Korangy F; Höchst B; Manns MP; Greten TF
Dig Dis; 2010; 28(1):150-4. PubMed ID: 20460904
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro.
Zhang HH; Mei MH; Fei R; Liao WJ; Wang XY; Qin LL; Wang JH; Wei L; Chen HS
Int J Oncol; 2010 Apr; 36(4):841-8. PubMed ID: 20198327
[TBL] [Abstract][Full Text] [Related]
16. Immune cell therapy for hepatocellular carcinoma.
Mizukoshi E; Kaneko S
J Hematol Oncol; 2019 May; 12(1):52. PubMed ID: 31142330
[TBL] [Abstract][Full Text] [Related]
17. Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells.
Ruf B; Heinrich B; Greten TF
Cell Mol Immunol; 2021 Jan; 18(1):112-127. PubMed ID: 33235387
[TBL] [Abstract][Full Text] [Related]
18. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma.
Barsch M; Salié H; Schlaak AE; Zhang Z; Hess M; Mayer LS; Tauber C; Otto-Mora P; Ohtani T; Nilsson T; Wischer L; Winkler F; Manne S; Rech A; Schmitt-Graeff A; Bronsert P; Hofmann M; Neumann-Haefelin C; Boettler T; Fichtner-Feigl S; van Boemmel F; Berg T; Rimassa L; Di Tommaso L; Saeed A; D'Alessio A; Pinato DJ; Bettinger D; Binder H; John Wherry E; Schultheiss M; Thimme R; Bengsch B
J Hepatol; 2022 Aug; 77(2):397-409. PubMed ID: 35367533
[TBL] [Abstract][Full Text] [Related]
19. [Perspectives on immunotherapy for hepatocellular carcinoma].
Schmidt N; Büttner N; Thimme R
Dtsch Med Wochenschr; 2013 Apr; 138(14):740-4. PubMed ID: 23533044
[TBL] [Abstract][Full Text] [Related]
20. Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives.
Jacquelot N; Seillet C; Souza-Fonseca-Guimaraes F; Sacher AG; Belz GT; Ohashi PS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
